United States — Food and Drug Administration & Takeda Pharmaceutical Company

United States — Food and Drug Administration: The FDA granted approval to Orzeyful, marking the first drug to target the underlying cause of narcolepsy type 1. The agency highlighted the drug's mechanism and granted breakthrough therapy designation and priority review.

Takeda Pharmaceutical Company: Takeda developed and received FDA approval for Orzeyful, its first-in-class orexin agonist for narcolepsy type 1. This approval strengthens its pipeline and market position, though the company expects no significant impact on its fiscal 2027 forecast.

United States — Food and Drug Administration: The United States — Food and Drug Administration (FDA) has granted two Fast Track Designations to IBI363, indicating its potential to address unmet medical needs and expedite its development and review process.

Takeda Pharmaceutical Company: Takeda Pharmaceutical Company is co-developing IBI363 with Innovent Biologics and will exclusively commercialize it globally outside the U.S. and greater China. The positive clinical results for IBI363 strengthen Takeda's oncology portfolio and future revenue potential.

United States — Food and Drug Administration: The United States — Food and Drug Administration is currently reviewing the New Drug Application for rusfertide.

Takeda Pharmaceutical Company: Takeda Pharmaceutical Company is the licensee for rusfertide, another peptide discovered by AnBogen Therapeutics.

United States — Food and Drug Administration: The United States — Food and Drug Administration is currently reviewing the New Drug Application for rusfertide for the treatment of polycythemia vera.

Takeda Pharmaceutical Company: Takeda Pharmaceutical Company is licensed to develop and commercialize rusfertide, another peptide therapeutic discovered by AnBogen Therapeutics.

United States — Food and Drug Administration: The FDA is reviewing the NDA for rusfertide. This event does not affect the FDA.

Takeda Pharmaceutical Company: Takeda is the licensee of rusfertide, which is under FDA priority review. No direct impact from this event.

United States — Food and Drug Administration: The FDA has cleared several of Ascentage Pharma's Phase III trials, but this event does not directly involve the FDA.

Takeda Pharmaceutical Company: Takeda is a partner of Ascentage Pharma, but this event does not directly involve Takeda.

Takeda Pharmaceutical Company: Takeda Pharmaceutical Company Limited is a funding partner for the project, supporting the research into Alzheimer s disease biomarkers.

Takeda Pharmaceutical Company: Takeda Pharmaceutical Company presented positive additional results from two pivotal studies for its drug oveporexton, which could redefine the standard of care for narcolepsy type 1, potentially increasing its market share and revenue in the pharmaceutical industry. Its shares were down 2.18% on the day of the announcement, but the long-term outlook is positive if the drug is approved.